BioCentriq

BioCentriq

制药业

Newark,New Jersey 4,312 位关注者

Manufacturing Partner for Cell Therapy Process Development and Clinical Production

关于我们

BioCentriq is an established, highly collaborative, global cell therapy CDMO. The company has been successfully manufacturing drug products for use in human clinical trials since 2022. In June of 2023, BioCentriq launched its LEAPTM Advanced Therapy Platform which helps cell therapy developers move from contract to clinic in as short as six months. With industry recognized scientists, engineers, analysts, and manufacturing specialists, established quality systems and modern infrastructure, BioCentriq is a proven strategic partner for the development and manufacturing of both autologous and allogeneic cell therapy products. The company was purchased by GC of South Korea for $73M in May 2022. On behalf of McKinsey, BioCentriq operates the only Innovation & Learning Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences. Visit www.biocentriq.com to learn more.

网站
https://biocentriq.com/
所属行业
制药业
规模
51-200 人
总部
Newark,New Jersey
类型
私人持股
创立
2019
领域
Cell therapy、clinical manufaturing、process development、Tech Transfer、Cell Banking、Upstream Processing、Downstream Processing、Monoclonal Antibodies、GMP Production、Cell Banking、Viral Banking、Allogeneic Cell Therapies、Autologous Cell Therapies、Workforce Development和Corporate Training

地点

BioCentriq员工

动态

相似主页

查看职位

融资

BioCentriq 共 2 轮

上一轮

A 轮

US$29,200,000.00

Crunchbase 上查看更多信息